Post di Springer Healthcare Italia

Un centrale articolo che illustra le linee guida internazionali su come dovrebbe essere valutata la qualità di vita nei pazienti con #mielodisplasia. Sfide, strategie di valutazione, approcci statistici e tanto altro 👉 https://lnkd.in/dXEVDbVW Fondazione GIMEMA - Franco Mandelli Onlus #AILRoma #GIMEMA #clinicaltrials #hematology

🚀Exciting developments from EHA 2024! Dr Hanne Norseth from the Oslo Myeloma Center presented the results of the phase I/II TG01 study. This study explores the safety and efficacy of the TG01/QS-21 vaccine in patients with KRAS or NRAS mutations. While the vaccine was well-tolerated, further evaluation is needed to determine its clinical efficacy. Stay tuned for more updates on this innovative approach in multiple myeloma treatment. For all EHA 2024 videos, find the link in the comments! 👇 #MediMix #Hematology #MultipleMyeloma #Innovation

Happy to announce the publication of my latest article, "Nanotechnology strategies to address challenges in topical and cellular delivery of siRNAs in skin disease therapy" in the esteemed journal "Advanced Drug Delivery Reviews" by Elsevier as part of my doctoral work. I thank Maria Vitoria Bentley for the supervision and support and the co-authors, Milena Finazzi Morais, for their dedication and commitment. In this article we bring together the main challenges of topical and cellular delivery of siRNAs, explore strategies to overcome them, and finally, an overview of the application and therapeutic effects of siRNAs (delivered in nanoparticles and physical methods) in wound healing diseases, skin cancer, psoriasis, dermatitis among other dermatological diseases is shown. We hope that this review will expand knowledge about the delivery barriers of siRNA (and other nucleic acids) and provide new insights to improve their bioavailability and therapeutic effects, and thus bring new hope for therapy of dermatological diseases. Access here: https://lnkd.in/dEhysGVS Thanks to funding: FAPESP CNPq SisNANO USP Faculdade de Ciências Farmacêuticas de Ribeirão Preto - USP NanoGeneSkin Bentley's Laboratory #Nanotechnology #genetherapy #skindisease #dermatology #nucleicacid #nanoparticle

Masterclass in Neuro-Oncology II edition High and Low Grade Gliomas L’obiettivo della masterclass è condividere e approfondire le nozioni più rilevanti sullo stato dell’arte della diagnosi e del trattamento dei pazienti con gliomi di basso e altro grado. Negli ultimi anni la ricerca scientifica, supportata dalla tecnologia, ci ha fornito una migliore comprensione delle alterazioni molecolari alla base della crescita di questi tumori come anche nuovi elementi per la classificazione istologica-molecolare e l’imaging. Questo ha continua ripercussione su nuove prospettive sistemiche di cura, con la possibilità di utilizzare nuovi trattamenti e nuovi protocolli di ricerca clinica con l’obiettivo primario di offrire ai pazienti aggiuntive chances terapeutiche e una migliore qualità di vita con un supporto adeguato. RESPONSABILI SCIENTIFICI Dr. Giuseppe Lombardi , Dirigente Medico U.O.C. Oncologia 1, Istituto Oncologico Veneto, IRCCS, Padova, Coordinatore Gruppo Neuro-Oncologico Interdipartimentale di Padova SEGRETRIA SCIENTIFICA: Mario Caccese , Dirigente Medico, Istituto Oncologico Veneto, IRCCS, Padova Marta Padovan, Dirigente Medico, Istituto Oncologico Veneto, IRCCS, Padova. https://lnkd.in/d9c-bTA9 Istituto Oncologico Veneto IOV - IRCCS Università degli Studi di Padova AIOM | Associazione Italiana di Oncologia Medica SINch, Società Italiana di Neurochirurgia AIRO - Associazione Italiana di Radioterapia ed Oncologia Clinica #AssociazioneItalianadiNeuroOncologia AIGOM Associazione Italiana #ROPI #AssociazioneItalianadiMedicinaNucleare

Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice Sagar Gaikwad et al. SCIENCE TRANSLATIONAL MEDICINE 3 Jul 2024 Vol 16, Issue 754 Gli aggregati tau patologici causano il declino cognitivo nelle tauopatie neurodegenerative, inclusa la malattia di Alzheimer (AD). Questi aggregati sono prevalenti all'interno dei compartimenti intracellulari. Le attuali immunoterapie tau hanno mostrato un'efficacia limitata nell'eliminazione degli aggregati tau intracellulari e nel miglioramento delle funzioni cognitive negli studi clinici. In questo studio è riportato l’effetto di un anticorpo monoclonale tossico specifico per la conformazione tau-2 (TTCM2), che ha riconosciuto selettivamente gli aggregati tau patologici nei tessuti cerebrali di pazienti con AD, demenza con corpi di Lewy (DLB) e paralisi sopranucleare progressiva (PSP). TTCM2 ha inibito in maniera significativa l'attività di semina tau, un meccanismo essenziale alla base della progressione della tauopatia. Per colpire efficacemente gli aggregati tau intracellulari e garantire un rapido rilascio al cervello, TTCM2 è stato caricato in micelle (TTCM2-ms) e somministrato per via intranasale. TTCM2-ms somministrato per via intranasale entra in modo efficiente nel cervello nei topi hTau-tauopatia, prendendo di mira la tau patologica nei compartimenti intracellulari. Inoltre, una singola dose intranasale di TTCM2-ms ha eliminato efficacemente la tau patologica, aumentando le proteine sinaptiche e migliorando le funzioni cognitive nei topi anziani con tauopatia. TRIM21 è risultato essenziale per la clearance mediata da TTCM2-ms della patologia tau. Questo studio potrebbe essere prezioso nella progettazione di immunoterapie tau efficaci per l’AD e altre tauopatie. https://lnkd.in/d43W2x-M

Thrilled to present our data on novel medication pathways, basic physiology, and insights into surgical techniques for male #LUTS at this year‘s #AUA24 in San Antonio, #Texas. Shoutout to Prof. Christian Gratzke for organizing a perfectly curated podium session on BPH: Basic Research & Pathophysiology! Excerpt from PD03-02: #QS11 is a small molecule #ARFGAP1 inhibitor and activator of #Wnt/ß-catenin signaling pathway, sourced from Tocris Bioscience, promoting #prostate smooth muscle contraction. These interesting data may help to explain our findings regarding immunomodulatory imde drugs (IMiDs), presented at this year‘s #EAU24 in #Paris. #IMiDs interfere with the Wnt/ß-catenin signaling pathway, blocking contractile mechanisms in the lower urinary tract. This discovery of potential novel mechanisms of smooth muscle contraction provide the basis for bench to bedside #translational solutions for the #treatment and #care of #LUTS #BPH and #OAB by introducing novel #pharmaceutical options in the #future! Data are from our #research group focusing on basic and clinical research in #urological diseases, particularly benign prostatic hyperplasia, voiding dysfunction, prostate cancer, and minimally invasive surgery. Special thanks to Ludwig-Maximilians-Universität München, LMU Klinikum München, Department of #Urology for providing the necessary research facilities, and for #funding through Munich Medical and Clinician Scientist Program (MCSP) by Deutsche Forschungsgemeinschaft (DFG) - German Research Foundation, and Deutsche Gesellschaft für Urologie. American Urological Association #healthcare #research #project #growth #leadership #luts #bph #germany #munich #benchtobedside #sanantonio #usa #aua #eau #knowledge

Breaking Barriers Through Multi-Disciplinary Osteoarthritis (OA) Research - the OARSI - Osteoarthritis Research Society International World Congress in Vienna, April 18-21 2024 Scientists from Chondrometrics GmbH and Paracelsus Medizinische Privatuniversität (PMU) will deliver oral & poster presentations on advanced quantitative measurement of articular tissue pathology. The #OARSI congress (https://lnkd.in/gyqNm8aH) is the largest global platform of OA research. Attracting professionals from all disciplines in academia & industry, >1,000 attendees from >40 countries are expected in Vienna. OARSI is the premier society to advance research on #OA, a condition affecting >600 million people worldwide. Felix Eckstein, Professor at PMU & CEO at Chondrometrics recently became the Austrian Ambassador for OARSI. He enthusiastically anticipates the World Congress to be hosted in Austria, where his research group is affiliated with the Ludwig Boltzmann Institute Arthritis and Rehabilitation (#LBIAR), led by Tanja Stamm. On April 19 (8:45-10:15; Abstract No20) he is speaking on the analysis of MR images with and without blinding to acquisition order, and whether it impacts effect sizes of “#Sprifermin” on cartilage thickness in the FORWARD trial. He is supported by Formation Bio, a company aiming to develop Sprifermin as a putative disease-modifying OA drug (#DMOAD). In poster No90 he presents on clinical validation of automated measurement of cartilage composition by MRI (#T2) using deep learning (#AI), with researchers from Charité (Nicholas Brisson & Univ.-Prof. Dr. Ing. Georg Duda) & 4P-Pharma (francis berenbaum) from the OVERLOAD & OA-BIO Eurostars projects. Susanne Maschek presents poster No492 on the impact of MRI scanner field strength on cartilage T2. A low-field magnet (0.55 Tesla) suitable for outpatient settings is compared with clinical (1.5, 3 & 7T) scanners, in collaboration with Frank W. Roemer, M.D.'s group & #Siemens Healthcare. Anna Wisser will present a poster (No207) on the impact of diabetes mellitus on physical function & thigh muscle strength in Osteoarthritis Initiative (#OAI) participants. The work is part of a broader project on metabolism and tissue function within the #LBIAR. Clemens Heistracher & Jana Eder contribute poster No084 on fully #unsupervised automated segmentation of thigh muscle & adipose tissue, without using labeled data, entailing important advances in automated segmentation technology. Wolfgang Wirth presents a poster (No491) on automated image segmentation, comparing different MRI sequences in detecting OA cartilage thickness change (co-authors Akshay Chaudhari & David Hunter). A 2nd poster (No493) on #sex-differences in radiographic knee joint space width & cartilage morphometry in size-matched subjects is part of a broader initiative, characterizing “sexual dimorphism” in tissue as risk factors for knee OA, recently submitted to a Special Issue of Osteoarthritis and Cartilage Journal.

✈️ Prossima fermata…Croazia!🇭🇷 Unisciti al team SOPHiA GENETICS in occasione del 22° Congresso Annuale dell’Associazione Europea di Ematopatologia (EA4HP), a Dubrovnik, Croazia, e scopri di più sugli ultimi sviluppi nel campo dell’ emato-oncologia e altro ancora!  #EA4HP #Haematopathology #hematology #hematooncology #precisionmedicine

Corso ECM "La gestione multidisciplinare integrata del paziente con carcinoma della prostata: proposta di un modello operativo. La recidiva biochimica" Responsabili scientifici: Michele Boero, Francesco Atzori, Giorgio Muscas Cagliari 1 Marzo Sala Thun - Ospedale Microcitemico Iscrizione gratuita Per info e iscrizioni https://lnkd.in/ggihkFg #Medici di: #Anatomia #Patologica #GeneticaMedica #MedicinaGenerale #MedicinaNucleare #Oncologia #Radiodiagnostica #Radioterapia #Urologia #Biologi #Genetica #PatologiaClinica

Relationship between Age, Histologic Grade, Tumour Size, Immunohistochemical Biomarkers Expressions, and Molecular Subtypes of Invasive Breast Carcinoma in Ilorin, Nigeria. https://lnkd.in/dTipB5fN